Systemic Sclerosis and Scleroderma-Related Lung Disease
The Scleroderma Research Foundation focuses on clinical research in systemic sclerosis, with particular attention to interstitial lung disease associated with scleroderma (SSc-ILD).
- SSc-ILD
- Systemic sclerosis
- Scleroderma
Its funded research activity is centered on pulmonary complications of scleroderma, especially conditions affecting breathing and lung function.
Pulmonary Function and Respiratory Outcomes
Clinical interest extends to measures of lung function in people with SSc-ILD, including outcomes relevant to forced vital capacity (FVC).
- Forced vital capacity (FVC)
- Lung function
- Respiratory impairment
This area reflects a focus on how scleroderma affects breathing capacity and pulmonary health.
Investigational Therapies for Fibrotic Lung Disease
The sponsor supports research evaluating investigational treatments for the lung complications of scleroderma, with attention to therapies aimed at fibrotic disease processes.
- Investigational treatments
- Fibrotic lung disease
- Placebo-controlled assessment
These studies are aligned with therapeutic development for progressive lung involvement in connective tissue disease.
Multinational Clinical Research in Rare Disease
Research activity spans multiple collaborating sites and countries, supporting clinical investigation in a rare autoimmune disease setting.
- Rare disease research
- Autoimmune disease
- International site collaboration
The sponsor’s current trial network includes broad geographic participation in studies of scleroderma-associated interstitial lung disease.
